home / stock / nnbxf / nnbxf short
Short Information | Nanobiotix SA (OTCMKTS:NNBXF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 2,056 |
Total Actual Volume | 2,490 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 5 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 103 |
Average Short Percentage | 23.74% |
Is there a NNBXF Short Squeeze or Breakout about to happen?
See the NNBXF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
02-04-2021 | $18.35 | $18.35 | $18.35 | $18.35 | 1,000 | 1,000 | 100% |
02-02-2021 | $18.3 | $18.3 | $18.3 | $18.3 | 500 | 500 | 100% |
12-11-2020 | $16.25 | $16.25 | $16.25 | $16.25 | 426 | 92 | 21.6% |
12-10-2020 | $14.8183 | $14.95 | $14.95 | $14.8183 | 214 | 114 | 53.27% |
12-09-2020 | $15.35 | $15.35 | $15.35 | $15.35 | 250 | 250 | 100% |
11-30-2020 | $15.25 | $15.25 | $15.25 | $15.25 | 100 | 100 | 100% |
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...